Regulatory Professionals Salaries up 5.4%, RAPS Survey Finds
RAPS has released the results of its biennial survey of the global healthcare regulatory profession.
The Regulatory Affairs Professionals Society (RAPS) has released the results of its biennial survey of the global healthcare regulatory profession, which found regulatory professionals’ salaries on the rise and identified key drivers of higher compensation. The 2014 Scope of Practice & Compensation Report for the Regulatory Profession is downloadable and shows regulatory professionals’ base salaries increased by an average of 5.4% from 2012 to 2013.
Other key highlights include:
- Professionals holding a Regulatory Affairs Certification (RAC) credential earn 10.6% more than their peers.
- Regulatory intelligence and regulatory strategy represent an average of about 20% of regulatory professionals’ time.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
